Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Investing Activities (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash from Investing Activities for 16 consecutive years, with -$8.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 131.25% to -$8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.4 million through Dec 2025, down 92.45% year-over-year, with the annual reading at $27.4 million for FY2025, 92.45% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$8.0 million at Standard Biotools, down from -$6.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $318.1 million in Q1 2024, with the low at -$138.2 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is $15.7 million, with a median of -$868000.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 1419.96% in 2022, then soared 5071.66% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$10.8 million in 2021, then surged by 472.6% to $40.2 million in 2022, then plummeted by 132.59% to -$13.1 million in 2023, then surged by 296.13% to $25.7 million in 2024, then crashed by 131.25% to -$8.0 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$8.0 million, -$6.7 million, and $27.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.